Opsy Holding

Opsy Holding EBIT per Share

The EBIT per Share of Opsy Holding (OPSYH.SL) as of Oct 29, 2026 is -1.40 SEK. In the previous year, EBIT per Share was -14.32 SEK — a change of -90.22% (higher).

EBIT per Share

-1.40SEK

YoY

-90.22%

Last updated:

EBIT per Share of Opsy Holding is 2025 -1.40 SEK. EBIT per Share of Opsy Holding was 2024 -14.32 SEK. It decreases by -90.22% higher compared to the previous year.

The Opsy Holding EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
-766.01 SEK
Jan 1, 2019
-706.54 SEK
Jan 1, 2020
-365.39 SEK
Jan 1, 2021
-2.93 SEK
Jan 1, 2022
-2.52 SEK
Jan 1, 2023
-2.71 SEK
Jan 1, 2024
-14.32 SEK
Jan 1, 2025
-1.40 SEK
The Opsy Holding EBIT per Share history
YEAREBIT per ShareYoY
-1.40SEK-90.22%
-14.32SEK+428.04%
-2.71SEK+7.86%
-2.52SEK-14.08%
-2.93SEK-99.20%
-365.39SEK-48.28%
-706.54SEK-7.76%
-766.01SEK-28.47%
-1,070.86SEK+33.11%
-804.49SEK+2.59%
-784.19SEK+144.62%
-320.57SEK+44.16%
-222.37SEK-42.06%
-383.77SEK-10.56%
-429.10SEK+142.30%
-177.09SEK-1.38%
-179.57SEK+60.51%
-111.87SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Opsy Holding Stock analysis

What does Opsy Holding do? Opsy Holding AB develops a software platform for insurance companies and medical advisors, focusing on anti-metastatic therapies related to the Wnt-5a protein. The company's products target the metastatic process through specific small molecules that interact with Wnt-5a mechanisms. Insurance companies and medical advisors purchase the platform to integrate advanced therapeutic insights into their services. The company's primary market segment consists of healthcare technology providers seeking innovative solutions for metastasis research. Opsy Holding AB's software platform is designed to support medical advisors and insurance firms in evaluating small molecules that specifically interact with the Wnt-5a protein's role in metastasis. The company's focus on Wnt-5a mechanisms positions its products for specialized healthcare applications. Insurance companies use the platform to enhance their risk assessment models with advanced therapeutic data. The company's business model centers on providing a technology platform that bridges medical research and insurance applications. By targeting the Wnt-5a protein's role in metastasis, Opsy Holding AB offers a niche solution for healthcare technology providers. The platform's value lies in its ability to connect specific small molecule evaluations with practical applications in insurance and medical advisory services. Opsy Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Opsy Holding stock

EBIT per Share of Opsy Holding is -1.40 SEK in 2025.

EBIT per Share of Opsy Holding changed from -14.32 SEK to -1.40 SEK, representing a -90.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Opsy Holding since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Opsy Holding

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Opsy Holding